Ipca Mulls Merger Of US Formulations Units

Unichem And Bayshore Could Be Combined Into A Single Entity Under Newly Unveiled Plan

Ipca is considering merging its US generic formulations businesses Bayshore Pharmaceuticals and Unichem Pharmaceuticals USA into a single entity, according to newly-unveiled plans that will be considered by directors in a week’s time.

Disembodied hands putting together two jigsaw pieces
Ipca is considering a merger of Unichem and Bayshore • Source: Shutterstock

US generics players Bayshore Pharmaceuticals and Unichem Pharmaceuticals USA could soon be combined into a single US generic formulations player, under plans unveiled by Bayshore owner and Unichem majority shareholder Ipca Laboratories.

Ipca and Unichem both announced via BSE filings today that a meeting of the board of directors would be held...

More from Strategy

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By 

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By 

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

 
• By 

Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.

Endo Offloads Paladin As Shareholders Approve Mallinckrodt Merger

 
• By 

As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.

More from Business

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By 

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By 

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.